Lai Seong Hooi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4611421/publications.pdf

Version: 2024-02-01

471371 526166 3,090 27 17 27 citations h-index g-index papers 29 29 29 4041 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet, The, 2011, 377, 2181-2192.	6.3	2,087
2	Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology, 2005, 10, 504-510.	0.7	213
3	Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy. JAMA - Journal of the American Medical Association, 2022, 327, 1888.	3.8	103
4	Prevalence of chronic kidney disease in Asia: a systematic review and analysis. BMJ Global Health, 2022, 7, e007525.	2.0	73
5	A population-based study measuring the prevalence of chronic kidney disease among adults in West Malaysia. Kidney International, 2013, 84, 1034-1040.	2.6	69
6	Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases, 2016, 68, 371-380.	2.1	57
7	Asian Chronic Kidney Disease (CKD) Best Practice Recommendations - Positional Statements for Early Detection of CKD from Asian Forum for CKD Initiatives (AFCKDI). Nephrology, 2011, 16, no-no.	0.7	50
8	Lupus Nephritis. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 147-153.	2.2	50
9	Economic evaluation of centre haemodialysis and continuous ambulatory peritoneal dialysis in Ministry of Health hospitals, Malaysia. Nephrology, 2005, 10, 25-32.	0.7	46
10	Prevalence of chronic kidney disease and its associated factors in Malaysia; findings from a nationwide population-based cross-sectional study. BMC Nephrology, 2020, 21, 344.	0.8	38
11	Glomerular Filtration Rates in Asians. Advances in Chronic Kidney Disease, 2018, 25, 41-48.	0.6	37
12	Acute Kidney Injury Risk Assessment: Differences and Similarities Between Resource-Limited and Resource-Rich Countries. Kidney International Reports, 2017, 2, 519-529.	0.4	33
13	Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. Kidney International, 2018, 93, 1000-1007.	2.6	32
14	Complications after Tenckhoff Catheter Insertion: A Single-Centre Experience using Multiple Operators over Four Years. Peritoneal Dialysis International, 2010, 30, 509-512.	1.1	30
15	Risk of Peritoneal Dialysis-Related Peritonitis in a Multi-Racial Asian Population. Peritoneal Dialysis International, 2017, 37, 35-43.	1.1	23
16	Health related quality of life of dialysis patients in Malaysia: Haemodialysis versus continuous ambulatory peritoneal dialysis. BMC Nephrology, 2019, 20, 151.	0.8	21
17	Increasing home based dialysis therapies to tackle dialysis burden around the world: A position statement on dialysis economics from the 2nd Congress of the International Society for Hemodialysis. Nephrology, 2011, 16, 53-56.	0.7	20
18	The Effect of Lowering LDL Cholesterol on Vascular Access Patency. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 914-919.	2.2	19

#	Article	IF	CITATIONS
19	Cost utility analysis of end stage renal disease treatment in Ministry of Health dialysis centres, Malaysia: Hemodialysis versus continuous ambulatory peritoneal dialysis. PLoS ONE, 2019, 14, e0218422.	1.1	16
20	The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics. American Journal of Nephrology, 2021, 52, 827-836.	1.4	15
21	Increasing homeâ€based dialysis therapies to tackle dialysis burden around the world: A position statement on dialysis economics from the 2nd Congress of the International Society for Hemodialysis. Hemodialysis International, 2011, 15, 10-14.	0.4	11
22	Dialysis Provision and Implications of Health Economics on Peritoneal Dialysis Utilization: A Review from a Malaysian Perspective. International Journal of Nephrology, 2017, 2017, 1-7.	0.7	11
23	Predictors of Arteriovenous Fistula Failure: A Post Hoc Analysis of the FAVOURED Study. Kidney360, 2020, 1, 1259-1269.	0.9	8
24	Nephrology in the Oceania–South East Asia region: perspectives and challenges. Kidney International, 2018, 94, 465-470.	2.6	7
25	Protocol for a randomised, open-label, parallel group, multicentre controlled study to evaluate the clinical performance and safety of Stay Safe Link compared with Stay Safe in patients with end-stage kidney disease on continuous ambulatory peritoneal dialysis. BMJ Open, 2019, 9, e024589.	0.8	3
26	A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial. Journal of Vascular Access, 2024, 25, 193-202.	0.5	2
27	Clinical effectiveness of a Malaysian-manufactured CAPD product: A randomised trial. Peritoneal Dialysis International, 2021, 41, 273-283.	1.1	1